This is the case of CETP inhibitors that, despite the failure in preventing cardiovascular events, have been shown to increase the survival rate in humanized models of sepsis [160], or recombinant human LCAT, that, by reducing HDL-bound SAA and increasing HDL-bound apoA-I as well as HDL functionality [161], could exert protective effect also against SARS-Cov2 infections [162]. This evidence concerns the gene CETP and Sepsis.